SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Under the Securities Exchange Act of 1934
(Amendment No. 2)*
Entasis Therapeutics Holdings Inc.
(Name of Issuer)
(Title of class of securities)
June 11, 2020
(Date of event which requires filing of this statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)
☒ Rule 13d-1(c)
☐ Rule 13d-1(d)
The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No.: 293614103
Name of Reporting Person:
Novo Holdings A/S
Check the Appropriate Box if a Member of Group (See Instructions):
(a) ☐ (b) ☐
SEC Use Only:
Citizenship or Place of Organization:
Sole Voting Power:
Shared Voting Power:
Sole Dispositive Power:
Shared Dispositive Power:
Aggregate Amount Beneficially Owned by Each Reporting Person:
Check if the Aggregate Amount in Row (11) Excludes Certain Shares:
Percent of Class Represented By Amount In Row (11):
Type of Reporting Person:
Based upon 27,291,563 shares of the Issuers Common Stock, comprised of 14,614,073 shares of Common Stock outstanding as of April 30, 2020, as reported in the Issuers Form 10-Q filed with the Securities and Exchange Commission (the SEC) on May 5, 2020 and 12,677,490 shares of Common Stock issued by the Company pursuant to a private placement that closed on June 11, 2020 as reported in the Issuers 8-K filed with the SEC on June 11, 2020.
This Amendment No. 2 amends the Schedule 13G originally filed with the SEC on October 1, 2018, as subsequently amended by Amendment No. 1 filed on February 5, 2020.
|Item 1.|| |
(a) Name of Issuer:
Entasis Therapeutics Holdings Inc.
(b) Address of Issuers Principal Executive Offices:
35 Gatehouse Drive
Waltham, MA 02451
|Item 2.|| |
(a) Name of Person Filing:
Novo Holdings A/S, a Danish limited liability company, is wholly owned by Novo Nordisk Foundation (the Foundation), a Danish commercial foundation. Novo Holdings A/S is the holding company in the group of Novo companies (currently comprised of Novo Nordisk A/S and Novozymes A/S) and is responsible for managing the Foundations assets, including its financial assets. Based on the governance structure of Novo Holdings A/S and the Foundation, the Foundation is not deemed to have any beneficial ownership of the securities of the Issuer held by Novo Holdings A/S.
(b) Address or Principal Business Office or, if none, Residence:
Tuborg Havnevej 19
2900 Hellerup, Denmark
(c) Citizenship or Place of Organization:
Novo Holdings A/S: Denmark
(d) Title of Class of Securities:
(e) CUSIP Number:
|Item 3.|| |
If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
|Item 4.|| |
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
Amount beneficially owned:
Percent of class:
Number of shares as to which such person has:
(i) Sole power to vote or to direct the vote:
(ii) Shared power to vote or to direct the vote:
(iii) Sole power to dispose or to direct the disposition of:
(iv) Shared power to dispose or to direct the disposition of:
Novo Holdings A/S, through its Board of Directors (the Novo Board), has the sole power to vote and dispose of the securities of the Issuer held by Novo Holdings A/S (the Novo Shares). The Novo Board may exercise voting and dispositive control over the Novo Shares only with the support of a majority of the Novo Board. As such, no individual member of the Novo Board is deemed to hold any beneficial ownership or reportable pecuniary interest in the Novo Shares.
Based upon 27,291,563 shares of the Issuers Common Stock, comprised of 14,614,073 shares of Common Stock outstanding as of April 30, 2020, as reported in the Issuers Form 10-Q filed with the SEC on May 5, 2020 and 12,677,490 shares of Common Stock issued by the Company pursuant to a private placement that closed on June 11, 2020 as reported in the Issuers 8-K filed with the SEC on June 11, 2020.
|Item 5.|| |
Ownership of Five Percent or Less of a Class:
|Item 6.|| |
Ownership of More Than Five Percent on Behalf of Another Person:
|Item 7.|| |
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:
|Item 8.|| |
Identification and Classification of Members of the Group:
|Item 9.|| |
Notice of Dissolution of Group:
|Item 10.|| |
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|Dated: June 16, 2020||Novo Holdings A/S|
|By: Peter Haahr |
|Its: Chief Financial Officer|